Education
About Us
Working with TipRanks
Follow Us
Schrodinger (SDGR)
NASDAQ:SDGR
SDGR Stock Chart & Stats
$17.01
-$1.19(-5.63%)
At close: 4:00 PM EST
$17.01
-$1.19(-5.63%)
Day’s Range― - ―
52-Week Range$16.60 - $28.47
Previous CloseN/A
Volume166.74K
Average Volume (3M)1.20M
Market Cap
$1.29B
Enterprise Value$1.19B
Total Cash (Recent Filing)$400.99M
Total Debt (Recent Filing)$111.43M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 04, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding64,500,510
10 Day Avg. Volume1,185,482
30 Day Avg. Volume1,203,973
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.33
Price to Sales (P/S)6.75
P/FCF Ratio-8.51
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda-8.43
Forecast
1Y Price Target
$26.50Price Target Upside55.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.09
Revenue Forecast (FY)$251.79M
Bulls Say, Bears Say
Bulls Say
Operational EfficiencyManagement confirmed operating expenses should land below FY24 rates, reflecting the ability to execute on key cost-cutting and streamlining initiatives.
Revenue GrowthFY25 drug discovery revenues are now projected to be $49-52M, up from prior guidance of $45-50M, as the company's partner portfolio continues to execute.
Strategic FocusThe strategic re-shuffle and set-up for next year with potential upside from the predictive tox platform should usher in a new, more streamlined era of growth for Schrödinger.
Bears Say
Guidance ReductionManagement lowered FY25 guidance for software revenue growth to 8-13% from prior 10-15% due to expectations regarding the timing for pharma scale-up opportunities.
Market HeadwindsIndustry macroeconomic headwinds have persisted, placing pressure on topline growth for the software segment.
Program TerminationSDGR announced termination of the SGR-2921 (CDC7) program for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) due to 2 treatment-related deaths in the Ph1 dose escalation study.
Schrodinger News
SDGR FAQ
What was Schrodinger’s price range in the past 12 months?
Schrodinger lowest stock price was $16.60 and its highest was $28.47 in the past 12 months.
What is Schrodinger’s market cap?
Schrodinger’s market cap is $1.29B.
When is Schrodinger’s upcoming earnings report date?
Schrodinger’s upcoming earnings report date is Mar 04, 2026 which is in 103 days.
How were Schrodinger’s earnings last quarter?
Schrodinger released its earnings results on Nov 05, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.717 by $0.267.
Is Schrodinger overvalued?
According to Wall Street analysts Schrodinger’s price is currently Undervalued.
Does Schrodinger pay dividends?
Schrodinger does not currently pay dividends.
What is Schrodinger’s EPS estimate?
Schrodinger’s EPS estimate is -0.18.
How many shares outstanding does Schrodinger have?
Schrodinger has 64,500,510 shares outstanding.
What happened to Schrodinger’s price movement after its last earnings report?
Schrodinger reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.717. Following the earnings report the stock price went down -5.665%.
Which hedge fund is a major shareholder of Schrodinger?
Currently, no hedge funds are holding shares in SDGR
Schrodinger Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.50 (55.79% Upside)
$26.50 (55.79% Upside)
Blogger Sentiment
Bullish
SDGR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 67.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 12.4%
Last 30 Days ▼ 12.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.69%
12-Months-Change
Fundamentals
Return on Equity
-45.67%
Trailing 12-Months
Asset Growth
-2.34%
Trailing 12-Months
Company Description
Schrodinger
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Company Deck
SDGR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and operational efficiency improvements, but also noted challenges in maintaining software revenue growth expectations and managing industry-related delays. Despite a strong cash position, the company reported a net loss.View all SDGR earnings summariesSDGR Stock 12 Month Forecast
Average Price Target
$26.50
▲(55.79% Upside)
Technical Analysis
Ownership Overview
2.41% Insiders
21.55% Mutual Funds
20.62% Other Institutional Investors
31.15% Public Companies and
Individual Investors